In addition to technological advancements, the project uses a unique centralized approach to conduct clinical trials, to limit differences in sample or inter-site variability of assessments. Our innovative ‘multi-centre recruitment and single-centre execution’ approach is needed for sophisticated and standardized trial conduct. These trials have started loco-regionally by CHDR-LUMC-EMC yielding the Clinical Network for Trials in Dermatology (CONNECTED, www.dermaconnected.nl) which is now ready for national roll-out within this project. With this blueprint of the trial network the collaborative scene in dermatology has been set by the key stakeholders.
Skin disease profiling by an exploratory,
RWE study in Dermatology practice (Skinergy)
- AD= Atopic dermatitis
- CsA= Cyclosporin A
- IL4/IL13= Interleukin-4 & -13 inhibitor
- JAK= Janus kinase inhibitor
- CLE= Cutaneous lupus erythematosus
- HCQ= Hydroxychloroquine
- TCS= Topical corticosteroids
- MTX= Methotrexate
- CSU= Chronic spontaneous urticaria
- IgE= Anti-IgE antibody
- CsA= Cyclosporin A
- **BTK= Bruton's tyrosine kinase inhibitor
- HS= Hidradenitis suppurativa
- CLINDA/RIF= Clindamycin/Rifampicin
- SECU= Secukinumab
- TNF= TNF-α inhibitor
- MF= Mycosis fungoides
- CHLORM= Chlormethine
- TCS= Topical corticosteroids
- PUVA= photochemotherapy
- PSO= Psoriasis
- TNF= TNF-α inhibitor
- IL23= Anti-IL-23 treatment
- IL17 = Anti-IL-17 treatment
- HV= Healthy volunteer